JP3192765B2 - Tape preparation - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a tape preparation which is applied to the skin and used to administer a required drug through a biological membrane to a circulatory system.

[0002]

2. Description of the Related Art In general, in the case of oral administration of a drug, the absorption of the drug is always kept constant, since the absorbability of the drug depends on the pH value in the stomach or intestine, the presence or absence of contents, and the like. It is difficult to administer a fixed amount of the drug gradually over a long period of time. In oral administration, side effects may occur due to a sudden increase in blood concentration due to inconsistent absorption, and for drugs with a short half-life, the duration of effective blood concentration is shortened and sufficient The drug effect may not be maintained for a long time. In addition, injection administration has problems such as pain at the time of administration and inconvenience of the administration method.

[0003] In order to solve these problems,
Percutaneous absorption preparations are being actively promoted because a constant effective blood concentration can be maintained for a long time and simplicity and functionality can be expected to be improved.

In this type of transdermal preparation, it is not always easy to administer the drug to the circulatory system via the stratum corneum of the skin, which originally has a barrier function for preventing foreign substances from entering the body. In general, measures are taken to increase the permeability of a drug by adding an absorption enhancer to a base, or to increase the application area of a transdermal absorption preparation.

[0005] A tape preparation is a kind of transdermal absorption preparation and is a preparation in which an adhesive layer composed of an adhesive and a drug is laminated on one surface of a support. Since it has side effects, it is preferable that the area to be stuck is as small as possible within a range where sufficient drug efficacy is exhibited. That is, during the period when the tape preparation is applied to the skin, the pressure-sensitive adhesive layer is in contact with the skin surface, so that the skin in that part is prevented from normal functions, such as secretion, metabolism, expansion and contraction, etc. It is always stimulated by the components constituting the agent layer. As a result, erythema develops on the affixed portion of the skin, and in severe cases, eschar formation and edema formation, which may even last for several days after removal of the tape preparation. Therefore, in order to reduce such side effects, it is necessary to increase the skin permeability of the drug in the tape preparation and to reduce the application area. As such a tape preparation, a tape preparation to which an absorption enhancer for improving skin permeability of a drug per unit area has been proposed.

For example, JP-A-58-79918 discloses that an acrylic pressure-sensitive adhesive is added with at least one selected from the group consisting of polyoxyethylene alkyl ethers and polyoxyethylene alkyl phenyl ethers as an absorption promoter. It has been proposed.

Although polyoxyethylene alkyl ethers have an absorption promoting effect, they have skin irritation,
In order to improve this point, JP-A-3-44327 proposes to use a salt of a polyoxyethylene alkyl ether as an absorption promoter. It has also been proposed to use higher fatty acid esters as absorption promoters.

[0008] By using a polyoxyethylene alkyl ether salt alone or in combination with a higher fatty acid ester, transdermal absorbability is improved and skin irritation is reduced. There was a drawback that the sticking property was reduced.

[0009]

SUMMARY OF THE INVENTION In view of the above-mentioned disadvantages, the present invention has low skin irritation, excellent sticking properties, particularly excellent sticking properties during sweating, and excellent drug transdermal absorption. It is intended to provide a tape preparation which has the following properties.

[0010]

Means for Solving the Problems The phosphate used in the present invention is a compound represented by the general formula (1) or (2).

[0011]

Embedded image

[0012]

Embedded image

In the formula, R, R ¹ and R ² are an alkyl group or an alkylphenyl group. When the number of carbon atoms decreases, the effect of promoting absorption decreases, and when the number of carbon atoms increases, the skin becomes highly irritating. The number is limited to 4-22. Also,
R, R ¹ and R ² may be the same or different, and the alkyl group may be linear or have a branch.

In the formula, M, M ¹ and M ² are alkali metals, such as sodium and potassium.

L, m and n represent integers. As the number decreases, the absorption promoting effect decreases, and as the number increases, the skin becomes highly irritating. Therefore, the integers of l, m and n are from 2 to 16
Is limited to

Examples of the phosphate represented by the general formula (1) include sodium polyoxyethylene (4) lauryl ether phosphate, polyoxyethylene (10) sodium lauryl ether phosphate, and polyoxyethylene (8) oleyl. And sodium polyoxyethylene (4), preferably sodium lauryl ether phosphate and polyoxyethylene (10).
It is sodium lauryl ether phosphate.

Examples of the phosphate represented by the general formula (2) include potassium dipolyoxyethylene (4) nonylphenyl ether phosphate and sodium dipolyoxyethylene (8) oleyl ether phosphate.

The above phosphates may be added alone or in combination of two or more. When the amount of the phosphate is small, the transdermal absorbability of the drug is reduced, and when the amount is large, the irritation to the skin is reduced. Therefore, it is preferable that the amount of 0.1 is contained in the pressure-sensitive adhesive layer.
It is 1 to 10% by weight, more preferably 0.5 to 5% by weight.

The diester used in the present invention is obtained from an aliphatic dicarboxylic acid and an alcohol.

The aliphatic dicarboxylic acid has 10 carbon atoms.
When the number of carbon atoms exceeds 2, the sticking property of the pressure-sensitive adhesive decreases.
And oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, sebacic acid, maleic acid, fumaric acid and the like.

When the alcohol has more than 20 carbon atoms, the sticking property of the pressure-sensitive adhesive is reduced. Therefore, the alcohol is limited to 1 to 20 carbon atoms. For example, methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol Alcohol, sec-butyl alcohol,
Examples include tert-butyl alcohol, hexyl alcohol, pentyl alcohol, heptyl alcohol, octyl alcohol, decyl alcohol, cetyl alcohol and the like, with alcohols having 1 to 4 carbon atoms being preferred.

As the diester, diethyl adipate, diisopropyl adipate, diethyl sebacate,
Diisopropyl sebacate and the like are preferably used. When the amount of the diester added is small, the adhesive property of the pressure-sensitive adhesive is reduced, and when the amount is large, the pressure-sensitive adhesive becomes sticky. Therefore, the content is preferably 1 to 30% by weight, more preferably 2 to 15% by weight in the pressure-sensitive adhesive layer. %.

In order to further improve the transdermal absorbability of the drug, other absorption enhancers may be added in addition to the phosphate.

The pressure-sensitive adhesive of the tape preparation used in the present invention may be any as long as it can dissolve the drug and has pressure-sensitive adhesiveness that can be fixed to the skin or mucous membrane for a long time at normal temperature. Preferred pressure-sensitive adhesives include an acrylic pressure-sensitive adhesive, a rubber-based pressure-sensitive adhesive, and a silicone-based pressure-sensitive adhesive.

The acrylic pressure-sensitive adhesives may have 1 to 1 carbon atoms.
8, preferably 4 to 18 aliphatic alcohols and (meth)
Examples include homopolymers and copolymers of alkyl (meth) acrylate obtained from acrylic acid and copolymers of alkyl (meth) acrylate and other functional monomers.

Examples of the alkyl (meth) acrylate include butyl (meth) acrylate and isobutyl (meth) acrylate.
Acrylate, hexyl (meth) acrylate, octyl (meth) acrylate, 2-ethylhexyl (meth)
Examples include acrylate, isooctyl (meth) acrylate, decyl (meth) acrylate, isodecyl (meth) acrylate, lauryl (meth) acrylate, stearyl (meth) acrylate, methyl acrylate, and ethyl acrylate.

Examples of the functional monomer include a monomer having a hydroxyl group, a monomer having a carboxyl group,
Examples include a monomer having an amide group, a monomer having an amino group, and a monomer having a pyrrolide ring. Examples of the monomer having a hydroxyl group include hydroxyalkyl (meth) acrylates such as 2-hydroxyethyl (meth) acrylate and 2-hydroxypropyl (meth) acrylate. Examples of the monomer having a carboxyl group include α, β unsaturated carboxylic acids such as acrylic acid and methacrylic acid, monoalkyl malates such as butyl malate, maleic acid, fumaric acid, crotonic acid and the like. Maleic anhydride is used as well as maleic acid. Examples of the monomer having an amide group include alkyl (meth) acrylamide such as acrylamide, dimethylacrylamide, and diethylacrylamide, N-alkoxymethyl (meth) acrylamide such as butoxymethylacrylamide, and ethoxymethylacrylamide, and diacetone acrylamide. As the monomer having an amino group,
Dimethylaminoethyl acrylate is exemplified. Examples of the monomer having a pyrrolidone ring include N-vinyl-2-pyrrolidone.

The copolymer may be further copolymerized with a copolymerizable monomer having no functional group. Examples of the copolymerizable monomer include vinyl acetate, styrene, and the like.
α-methylstyrene, vinyl chloride, acrylonitrile,
Examples include ethylene, propylene, and butadiene.
The pressure-sensitive adhesive preferably contains 50% by weight or more of an alkyl (meth) acrylate as a (co) polymerization component.

If necessary, a polyfunctional monomer may be further added to the acrylic pressure-sensitive adhesive and copolymerized with another monomer component. By the addition of this polyfunctional monomer,
Crosslinking occurs between the resulting polymers, which increases the internal cohesion of the adhesive. Therefore, the so-called glue residue phenomenon at the time of peeling is almost eliminated irrespective of the properties of the attached skin and the amount of perspiration. In addition, the addition of the polyfunctional monomer has no adverse effect on the drug release and low skin irritation. Examples of such polyfunctional monomers include di (meth) acrylate, tri (meth) acrylate, and tetra (meth) acrylate.
It is not limited to this. More specifically, hexamethylene glycol di (meth) acrylate, octamethylene glycol di (meth) acrylate obtained by combining polymethylene glycols such as hexamethylene glycol and octamethylene glycol with (meth) acrylic acid, and the like. Di (meth) acrylate, di (meth) acrylate, trimethylolpropane tri (meth) acrylate and glycerin tri (meth) obtained by combining polyalkylene glycols such as polyethylene glycol and polypropylene glycol with (meth) acrylic acid. A) tri (meth) acrylates such as acrylates, and tetra (meth) acrylates such as pentaerythritol tetra (meth) acrylate. Two or more of these polyfunctional monomers may be added. The amount of the polyfunctional monomer to be added is 0.5% by weight or less based on all the monomers used for the production of the pressure-sensitive adhesive.

The acrylic pressure-sensitive adhesive may optionally contain a tackifier such as a rosin-based resin, a polyterpene resin, a cumarone-indene resin, a petroleum-based resin, or a terpene-phenol resin.

Examples of the rubber-based pressure-sensitive adhesive include natural rubber, styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, and styrene-
Olefin-styrene block copolymer, polyisoprene, polybutene, polyisobutylene, 100 parts by weight of rubber elastic body such as ethylene-vinyl acetate copolymer, for example, rosin resin, polyterpene resin, cumarone-indene resin, petroleum resin, 20 to 200 parts by weight of a tackifier such as a terpene-phenol resin and, if necessary,
Liquid polybutene, mineral oil, lanolin, liquid polyisoprene, liquid polyacrylate and other softening agents, fillers such as titanium oxide, antioxidants such as butylhydroxytoluene and the like are added in appropriate amounts.

Examples of the silicone-based pressure-sensitive adhesive include those containing polydimethylsiloxane as a main component.

Examples of adhesives having good affinity for water include alkali metals such as alkali metal alginate, gelatin, corn starch, and tragacanth gum; cellulosic polymers such as methylcellulose, hydroxyethylcellulose and carboxymethylcellulose; dextrin and carboxymethyl starch. And synthetic polymers such as polyvinyl alcohol, sodium polyacrylate, methoxyethylene-maleic anhydride copolymer, polyvinyl ether, and polyvinylpyrrolidone.

A plasticizer, a filler, an antioxidant, and the like may be added to the pressure-sensitive adhesive as required.

Drugs (bioactive substances) used in the present invention
Any drug may be used as long as it can penetrate a biological membrane transdermally, and typical drugs include isosorbide dinitrate, estradiol, and indomethacin.

However, the drug (bioactive substance) used in the tape preparation of the present invention is not limited to the above.
Examples of drugs include antipyretic analgesics, antiepileptics, antipsychotics, antidepressants / anxiolytics, antidepressants, hypnotics, sedatives, antispasmodics, muscle relaxants, autonomic nervous system, cerebral circulation・ Metabolism improving agents, inotropic agents, antianginal agents, agents for hypertension / arrhythmia, vasodilators, antihypertensive agents, vasopressors, diuretics, respiratory stimulants, antitussive expectorants, bronchodilators, asthma / nasal allergy treatment Agents, respiratory agents, cold remedies, antiemetic agents, antacids, antiulcer agents, laxatives, antidiarrheal intestinal agents, liver agents, pancreatic disease treatment agents, bile agents, female hormone agents, male hormone agents, Hypothalamic and pituitary hormones, ovulation inducers, diabetes insipidus, thyroid hormones, anabolic hormones, antithyroids, calcium metabolism, steroidal anti-inflammatory drugs, nonsteroidal anti-inflammatory drugs, anti-inflammatory Enzyme, antihistamine, antirheumatic, gout, Glucose-lowering agents, vitamins, hematopoietic agents, hemostatic agents, therapeutic agents for hyperlipidemia, antibiotics, antitumor agents, immunosuppressants, antidote agents, emetics, anthelmintics, antiprotozoal agents, hemorrhoids, genitourinary tract Preparations, local anesthetics, anticoagulants and the like.

Representative examples of each drug are shown below. Antipyretic anti-inflammatory analgesics include, for example, indomethacin, salicylic acid,
Glycol salicylate, aspirin, acetaminophen, diclofenac sodium, ibuprofen, sulindac, naproxen, ketoprofen, flufenamic acid, ibufenac, fenbufen, alclofenac, phenylbutazone, mefenamic acid, bendazac, piroxicam, flurbiprofen, pentazocine, And buprenorphine hydrochloride and butorphanol tartrate.

Examples of steroidal anti-inflammatory agents include hydrocortisone, prednisolone, fluocinolone acetonide, fludoxycortide, methylprednisolone, hydrocortisone acetate, triamcinolone acetonide, dexamethasone, betamethasone acetate, diflucortron valerate, and propionic acid. Clobetasol, fluocinonide and the like can be mentioned.

Examples of the vasodilator include diltiazem, verapamil, pentaerythritol tetranitrate, dipyridamole, isosorbide dinitrate, nifedipine, nitroglycerin and the like.

Examples of the agent for hypertension / arrhythmia include propanolol, atenolol, pindolol, quinidine sulfate, adimarin, alprenolol hydrochloride, metoprolol tartrate, nadolol, timolol maleate, disopyramide and the like.

Examples of the antihypertensive include clonidine hydrochloride, captopril, prazosin hydrochloride, penbutolol sulfate, guanabenz acetate, guanfacine hydrochloride, bunazosin hydrochloride, elanapril maleate, arotinolol hydrochloride, and bunitrolol hydrochloride.

Examples of antitussive expectorants include procaterol hydrochloride, terbutaline sulfate, fenoterol hydrobromide, tulobuterol hydrochloride, ambroxol hydrochloride, pyrbuterol hydrochloride, mabuterol hydrochloride, clenbuterol hydrochloride, trimethoquinol hydrochloride, formoterol fumarate and the like. can give.

Examples of the antitumor agent include 5-fluorouracil, 1- (2-tetrahydrofuryl) -5-fluorouracil, mitomycin C and the like. Examples of the local anesthetic include benzocaine, procaine, lidocaine, tetracaine and the like.

Examples of hormonal agents include steroid hormones such as estrogen, estradiol, testosterone, progesterone, and prostaglandin, and peptide hormones such as insulin. Examples of the therapeutic agent for asthma and nasal allergy include ketotifen fumarate, azelastine hydrochloride, sodium cromoglycate and the like.

Examples of the antihistamine include cycloheptadine hydrochloride, diphenhydramine hydrochloride, fenbenzamin, mequitazine and the like. Examples of the anticoagulant include heparin. Examples of antispasmodics include scopolamine, clofluperol and the like.

Examples of the cerebral circulation / metabolism improving agent include vinpocetine, flunarizine hydrochloride, nicardipine hydrochloride, brovincamine fumarate, dihydroergotoxine mesylate, ifenprodil tartrate, isoxpurine hydrochloride and the like.

Examples of the antidepressant / anxiolytic include maprotiline hydrochloride, etizolam, diazepam, bromazepam, amitriptyline hydrochloride, mianserin hydrochloride and the like. Examples of vitamin D preparations include alphacalcidol, ergocalciferol, and the like.

Examples of hypoglycemic agents include glibenclamide and gliclazide. As anti-ulcer agents, for example, crevobride malate, famotidine,
Glycopyrronium bromide and the like.

Examples of the sleeping pills include phenobarbital and amobarbital. Examples of the antibiotic include tetracycline, chloramphenicol, and the like.

The amount of these drugs to be added varies depending on the kind of the drug, the purpose of use of the tape preparation, and the like. However, it is preferable that the drug is percutaneously absorbed to exhibit a sufficient medicinal effect and not to lower the adhesiveness of the adhesive. 0.1 to 50% by weight in the adhesive layer
It is. The saturation solubility of the drug in the pressure-sensitive adhesive layer varies depending on the composition of the pressure-sensitive adhesive layer. By releasing the drug in the pressure-sensitive adhesive layer at a concentration as close as possible to its saturation solubility and preventing crystallization, a high release of the drug is obtained. However, there is no particular problem even if crystals of the drug are precipitated in the pressure-sensitive adhesive layer. It is also possible to encapsulate the drug or absorption enhancer and to provide a reservoir for the drug or absorption enhancer.

The pressure-sensitive adhesive layer of the present invention comprises the above-mentioned drug, phosphate, diester, pressure-sensitive adhesive and additives added as required.

To form the above-mentioned pressure-sensitive adhesive layer, an ordinary method for producing a pressure-sensitive adhesive tape can be applied. A typical example thereof is a solvent coating method, and in addition, a hot melt coating method, an electron beam curing emulsion coating method and the like are used. In order to form the pressure-sensitive adhesive layer by a solvent coating method, for example, a drug, an absorption enhancer or the like is dissolved or dispersed in an appropriate solvent, and the obtained solution or dispersion is added to the pressure-sensitive adhesive, and is applied to one surface of the support. Direct application
It is dried to form a pressure-sensitive adhesive layer having a required thickness. Alternatively, this solution or dispersion may be applied on a protective release paper, and the pressure-sensitive adhesive layer obtained after drying may be adhered to a support. The thickness of the pressure-sensitive adhesive layer varies depending on the purpose of use, but is preferably 10 to
200 μm.

In the tape preparation of the present invention, the pressure-sensitive adhesive layer is
It is laminated on one surface of the support.

As the support of the above-mentioned tape preparation, a support which is flexible but imparts a self-supporting property to the tape preparation and which prevents the volatilization and migration of the drug in the adhesive layer is preferably used. . Examples of the material for the support include cellulose acetate, ethyl cellulose, polyethylene terephthalate, plasticized vinyl acetate-vinyl chloride copolymer, nylon, ethylene-vinyl acetate copolymer, plasticized polyvinyl chloride, polyurethane, polyethylene, and polyvinylidene chloride. , Aluminum and the like. These materials are used, for example, as a single-layer sheet or film or a laminate of two or more sheets. Materials other than aluminum may be used as a woven or nonwoven fabric. As the support, a support made of a material having the property of following the skin surface is suitably used, and a laminate film of polyethylene terephthalate and an ethylene-vinyl acetate copolymer is particularly preferable. The thickness of the support is preferably 5 to 100 μm.

The tape preparation is usually provided with a release paper on its application surface to protect the surface of the adhesive base layer until use. As the release paper, one obtained by subjecting a polyethylene terephthalate film to a silicon treatment is often used, but the release paper is not limited to this. Release paper thickness is 1
000 μm or less, preferably 30 to 200 μm.

The resulting tape preparation is usually applied directly to the surface of the skin or mucous membrane for the purpose of percutaneously or transmucosally administering the drug to the circulatory system. Further, these tape preparations are sometimes applied to the skin or mucous membrane for the purpose of treating a diseased part of the skin or mucous membrane.

[0057]

According to the tape preparation of the present invention, by using the above-mentioned phosphate and diester, the release amount of the drug per unit area and unit time and the transferability of the drug into the skin are extremely improved. Does not deteriorate the sticking property. This reduces the barrier function of the stratum corneum by phosphate and enhances the effect of promoting absorption of the drug into the skin,
This is because the diester enhances affinity with the skin and suppresses a decrease in sticking property.

[0058]

Next, an embodiment of the present invention will be described. Hereinafter, "parts" means "parts by weight". The evaluation methods and measurement methods for the skin transfer test, skin irritation test and skin permeability test shown in the results are as follows.

1) Skin Transfer Test A test piece (10 cm ^{2 in} area) of a tape preparation was stuck to the depilated back of a Japanese white rabbit, and after 24 hours, this was peeled off and collected. The collected test piece was subjected to extraction treatment with methanol, and the residual amount of the drug in the tape preparation was measured by high performance liquid chromatography to determine the difference between the amount of the drug before the tape preparation was applied and the remaining amount after the application. This operation was repeated four times, and the skin transfer amount was represented by an average value obtained by dividing the total of the measured values by the number of repetitions of 4.

2) Skin irritation test The erythema state of the skin 1 hour after peeling off the tape preparation in the skin transfer test was visually observed and evaluated by the following five grades. 0: No erythema 1: Slightly discernible erythema 2: Obvious erythema 3: Moderate erythema 4: Strong erythema of the erythema The skin irritation of the tape preparation was calculated by dividing the sum of the scores in each test by 4 repetitions It was expressed as an average value.

3) Adhesion test A test piece of tape preparation (area 3.14 cm) was placed on the human forearm.
² ) Attached, 2 hours rest and 20km / h for 1 hour
After the sweating exercise by running, the sticking property of the tape preparation was determined as follows. ：: Sticking property at the time of sticking is maintained. Δ: Half the sticking property at the time of sticking is maintained. ×: Almost no sticking property at the time of sticking. Synthesis of Adhesives A and B A predetermined amount of the monomer and 400 parts of ethyl acetate shown in Table 1 were supplied to a separable flask equipped with a stirrer and a cooling device, and the temperature was raised to 60 ° C. while stirring and purging with nitrogen. A solution prepared by dissolving 2 parts of lauroyl peroxide in 100 parts of cyclohexane was divided into 10 parts, and 1 part of the solution was added to a separable flask to initiate polymerization. The remaining 9 was added at hourly intervals from the fifth hour after the start of the reaction, and the reaction was continued for another 19 hours after the addition was completed. For the purpose of adjusting the viscosity, 50 parts of ethyl acetate were added 5 times every 5 hours after the start of the reaction. After the completion of the reaction, the mixture was cooled, and ethyl acetate was added so that the solid content concentration became 35% by weight.

[0062]

[Table 1]

Preparation of pressure-sensitive adhesive C Styrene-isoprene-styrene block copolymer (Califlex TR1107 manufactured by Shell Chemical Co., Ltd.) 100
Part, alicyclic hydrogenated petroleum resin (Arakawa Chemical Co., Inc., Alcon-P90) 140 parts, polybutene (Nisseki Chemical Co., Ltd., H
V-300) 25 parts and cyclohexane 490 parts were supplied to a separable flask equipped with a stirrer and a cooling device, and 2
The mixture was stirred at 5 ° C. for 96 hours and dissolved to obtain an adhesive having a solid content of 35% by weight.

Examples 1 to 9, Comparative Examples 1 to 5 Predetermined amounts of pressure-sensitive adhesive, isosorbide dinitrate, estradiol, indomethacin, polyoxyethylene (4) sodium lauryl ether phosphate, polyoxyethylene (10) shown in Table 2 Sodium lauryl ether phosphate,
The diester and isopropyl myristate were fed to a dissolver and mixed uniformly. The obtained mixture is applied on a silicon-treated polyethylene terephthalate film (thickness: 38 μm), dried at 60 ° C. for 30 minutes to form an adhesive layer having a thickness of 80 μm, and then a thickness of 34 μm
Was transferred onto a polyethylene terephthalate-ethylene / vinyl acetate copolymer layer of Example 1 to obtain a tape preparation.

[0065]

[Table 2]

The obtained tape preparation was subjected to a skin transfer test, a skin irritation test and a skin sticking durability test, and the results are shown in Table 3.

[0067]

[Table 3]

[0068]

According to the tape preparation of the present invention, a phosphate represented by the general formula (1) or (2) is added to an adhesive as an absorption promoter and an aliphatic dicarboxylic acid having 2 to 10 carbon atoms. Since a diester obtained from an acid and an alcohol having 1 to 20 carbon atoms is added, the adhesive property is excellent, and the effect of absorbing a sufficient amount of the drug through the skin to exhibit the intended medicinal effect is excellent. It requires only a small patch area for drug administration, reduces skin damage and reduces skin irritation during long-term use.

Furthermore, since the tape preparation of the present invention can easily transdermally absorb a sufficient amount of the drug to exhibit the intended drug effect as described above, it is not necessary to mix a large amount of the drug. Since the effective blood concentration can be maintained for a long period of time, a sufficient drug effect can be obtained. In addition, since the sticking property is maintained well, the tape preparation does not peel off even when sweating is performed.

──────────────────────────────────────────────────続 き Continued on front page (58) Field surveyed (Int.Cl. ⁷ , DB name) A61K 9/70

Claims (1)

(57) [Claims] 1. An adhesive or a drug, represented by the following formula (1) or (2):
Phosphate represented and aliphatic dicarbo having 2 to 10 carbon atoms
Dies obtained from acid and alcohol having 1 to 20 carbon atoms
An adhesive layer made of tellurium is laminated on one side of the support
A tape preparation, characterized in that: Embedded image(Wherein R represents an alkyl group having 4 to 22 carbon atoms or an alkyl group)
Enyl group, M and M¹Is an alkali metal, l is 2 to 16
Each means an integer. )(Where R¹And R^TwoIs an alkyl group having 4 to 22 carbon atoms or
Alkylphenyl group, M ^TwoIs an alkali metal, m and n are
It means an integer of 2 to 16, respectively. )